Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
Nov 6, 2017 Company to host conference call today at 4:30 p.m. ETPivotal, randomized control trial in rGBM to initiate by end of 2017Combination trial with checkpoint inhibitor in rGBM to initiate by end of 2017Point-of-care tria...
PDF
Nov 6, 2017 - Update to survival data from Phase 1 Trial of Ad-RTS-hIL-12 to treat recurrent glioblastoma (GBM) to be presented - - Additional biomarker and biopsy data provides evidence of IL-12 driving immune response to GBM - BOSTON, Nov. 06, 2017 (GLOBE NEWSWIR...
PDF
Nov 1, 2017 BOSTON, Nov. 01, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on developing gene and cell-based immunotherapies for cancer, today announced that five abstracts highlighting data from the Company's adoptive cell-based therapeutic programs have been accepted for presentatio...
PDF
Oct 26, 2017 BOSTON, Oct. 26, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company developing new gene and cell-based immunotherapies for cancer, today announced that it will host a conference call and webcast slide presentation on Monday, November 6, 2017 at 4:30 p.m. ET to provide a corporate updat...
PDF
Oct 24, 2017
PDF
Oct 16, 2017 BOSTON, Oct. 16, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company developing new gene and cell-based immunotherapies for cancer, today announced that the first patient has been dosed in a new Phase 1 study of Ad-RTS-hIL-12 with veledimex for the treatment of pediatric brain tumors....
PDF
Oct 12, 2017 BOSTON, Oct. 12, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on developing gene and cell-based immunotherapies for cancer, today announced that three abstracts highlighting data from the Company's Ad-RTS-hIL-12 + veledimex program have been accepted for presentation at t...
PDF
Sep 28, 2017 BOSTON, Sept. 28, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focusing on new immunotherapies, announces the appointment of David Mauney, M.D., as Executive Vice President and Chief Business Officer, effective today.  ZIOPHARM also reports the details of an inducement award granted...
PDF
Sep 18, 2017 BOSTON, Sept. 18, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immun...
PDF
Sep 5, 2017 BOSTON, Sept. 05, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Rodman & Renshaw 19th Annual Global Investment Conference in New York on Tuesday, September 12, 2017 at 12:30 p.m. ET. ...
PDF
Page: FirstPrevious
2
... NextLast